CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial
CERo Therapeutics dosed the seventh patient overall, the fourth in the second cohort, of its Phase 1 CERTAIN-T trial of CER-1236 in hematologic malignancies including AML, MDS, and myelofibrosis. No dose-limiting toxicities were observed in the first three patients of the second cohort, and previously reported expansion of infused CER-1236 cells supports continued dose escalation.
Key figures
- Drug Name
- CER-1236
- Phase Of Trial
- Phase 1
- Cohort
- 2
- Patients treated
- 7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.